Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

• ClinicalTrials.gov Identifier: NCT03448718
• Recruitment Status: Recruiting
• First Posted: February 28, 2018
• Last Update Posted: February 11, 2020
• Sponsor: Matthew Galsky
• Collaborators: Icahn School of Medicine at Mount Sinai; AstraZeneca
• Information provided by (Responsible Party): Matthew Galsky, Hoosier Cancer Research Network

Study Description

Brief Summary:

This is a single arm open label multi-institutional phase II trial of olaparib monotherapy in subjects with metastatic urothelial cancer harboring somatic DNA damage response (DDR) alterations. The primary objective of the study is to estimate the objective response rate (per RECIST 1.1) to treatment with olaparib.

Condition or disease	Intervention/treatment	Phase
Metastatic Urothelial Cancer	Drug: Olaparib	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 30 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase 2 Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
• Actual Study Start Date: April 17, 2018
• Estimated Primary Completion Date: March 2022
• Estimated Study Completion Date: March 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Olaparib Monotherapy; The starting dose of olaparib tablets will be dependent on the subject's calculated creatinine clearance (CrCl). Subjects with a CrCl of ≥ 40 mL/min will start at a dose of olaparib tablets of 300 mg twice a day. Subjects with a CrCl of > 30 to < 40 mL/min will start at a dose of olaparib tablets 200 mg twice a day.	Drug: Olaparib; 1 cycle = 28 days. Subject's with calculated creatinine clearance (CrCl) of ≥ 40 mL/min will start at a dose of olaparib tablets of 300 mg twice a day. Subjects with a CrCl of > 30 to < 40 mL/min will start at a dose of olaparib tablets 200 mg twice a day.; Other Name: Lynparza

Outcome Measures

Primary Outcome Measures :

1. Objective Response Rate [ Time Frame: 36 Months ]
   Estimate the objective response rate (per RECIST 1.1 or MD Anderson Criteria for bone-only metastatic disease) to treatment with olaparib in subjects with metastatic urothelial cancer harboring somatic DDR alterations. Objective response rate will include confirmed complete response (CR) + confirmed partial response (PR) and will be determined as per RECIST 1.1.

Secondary Outcome Measures :

1. Progression-Free Survival [ Time Frame: 36 Months ]
   Progression-free survival is defined as the time from Day 1 of treatment until the criteria for disease progression is met as defined by RECIST 1.1 or death as a result of any cause.

Other Outcome Measures:

1. Overall Survival [ Time Frame: 36 Months ]
   Overall survival is defined as the time from Day 1 of treatment until death as a result of any cause.
2. Adverse Event Assessment [ Time Frame: 36 Months ]
   Assess all grade 3 and 4 adverse events as defined by the NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
• Age ≥ 18 years at the time of consent.
• ECOG Performance Status of ≤ 1 within 14 days prior to registration. Cisplatin-ineligible chemotherapy-naïve subjects (see inclusion criteria #8) may have an ECOG Performance Status of ≤ 2.
• Histological or cytological evidence/confirmation of urothelial cancer.
• Metastatic and/or unresectable (cT4b) urothelial cancer.

• Metastatic disease evaluable on imaging studies. Subjects may have measurable disease according to RECIST 1.1 or bone-only disease within 30 days prior to registration.

  • NOTE: Bone-only subjects are eligible if their disease can be documented/ evaluated by bone scans, CT or MRI. Their disease will be assessed using MD Anderson criteria.34
  • NOTE: Previously irradiated lesions are eligible as a target lesion only if there is documented progression of the lesion after irradiation.
• Somatic alteration in one of the following DDR genes as determined by genomic sequencing performed in a Clinical Laboratory Improvement Amendments (CLIA) laboratory. Somatic alterations will include nonsense, frameshift, splice-site or missense mutations or homozygous deletions. Subjects with alterations in DDR genes not included in the list below will be considered on a case by case basis after discussion with the sponsor-investigator. Subjects with germline alterations in DDR genes will be considered on a case by case basis and will be reviewed by the sponsor-investigator. At least 6 subjects will have BRCA or ATM alterations.
• Nucleotide Excision Repair: ERCC2, ERCC3,ERCC4, ERCC5, ERCC6
• Homologous Recombination: BRCA1, RAD52, BRCA2, RAD54L, RAD50, NBN RAD51, MRE11A, RAD51B, RAD51D, RAD51C, CTIP
• DNA Sensor: ATM, ATR, MDC1, ATRX, CHEK1, CHEK2
• Fanconi Anemia Pathway: PALB2, FANCE, BRIP1, FANCF, FANCA, FANCG FANCB, BLM, FANCC, FANCD2
• Base Excision Repair: XRCC2, XRCC3, XRCC4, XRCC5, XRCC6
• Other: MUTYH, RECQL4, POLQ, POLE, WRN
• A subject with prior brain metastasis may be considered if they have completed their treatment for brain metastasis at least 4 weeks prior to study registration, have been off of corticosteroids for ≥ 2 weeks, and are asymptomatic
• Subjects must have progressed despite at least 1 prior line of treatment for metastatic and/or unresectable urothelial cancer. However, cisplatin-ineligible (defined by a calculated creatinine clearance of >30 but < 60 mL/min OR CTCAE v4 Grade ≥ 2 audiometric hearing loss OR CTCAE v4 Grade ≥ 2 peripheral neuropathy OR ECOG PS = 2), and chemotherapy-naïve subjects are also eligible.
• Prior cancer treatment (systemic therapy or radiation therapy) must be completed at least 3 weeks prior to registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to Grade ≤ 1 or baseline.

• Demonstrate adequate organ function as defined in the table below. All screening labs to be obtained within 28 days prior to registration.

  • Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L
  • Hemoglobin (Hgb) ≥ 10 g/dL
  • Platelets ≥ 100 x 109/L
  • Calculated creatinine clearance ≥ 30 mL/min
  • Bilirubin ≤ 1.5 × upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) ≤ 2.5 × ULN (or ≤ 5 × ULN if liver metastases)
  • Alanine aminotransferase (ALT) ≤ 2.5 × ULN (or ≤ 5 × ULN if liver metastases)
• Female subjects must be postmenopausal or there must be evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on day 1.
• Females of childbearing potential must be willing to abstain from heterosexual activity or to use 2 forms of highly effective methods of contraception from the time of informed consent until 30 days after treatment discontinuation. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method. Males must be willing to abstain from heterosexual activity or to use 2 forms of highly effective methods of contraception from the time of informed consent until 90 days after treatment discontinuation.
• As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study
• All subjects must have adequate archival tissue available prior to registration (i.e., at least 15 unstained slides or paraffin block). Archival tissue should represent invasive or metastatic urothelial cancer with a preference for metastatic tissue if available. Subjects without adequate tissue may be considered on a case by case basis after discussion with the sponsor-investigator.

Exclusion Criteria

• Active infection requiring systemic therapy.
• Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
• Known additional malignancy that is active and/or progressive requiring treatment; subjects with other malignancies that have been definitively treated and who have been rendered disease free will be eligible.
• Prior treatment with a PARP inhibitor, including olaparib.
• Treatment with any investigational drug within 30 days prior to registration.
• Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
• Resting ECG with QTc > 470 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome.
• Concomitant use of known strong CYP3A inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is 2 weeks.
• Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
• Subjects with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AML.
• Major surgery within 2 weeks of starting study treatment and subjects must have recovered from any effects of any major surgery.
• Subjects considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan, history of pneumonitis, or any psychiatric disorder that prohibits obtaining informed consent.
• Subjects unable to swallow orally administered medication and subjects with gastrointestinal disorders likely to interfere with absorption of the study medication.
• Immunocompromised subjects, e.g., subjects who are known to be serologically positive for human immunodeficiency virus (HIV).
• Subjects with a known hypersensitivity to olaparib or any of the excipients of the product.
• Subjects with known active hepatitis (i.e. Hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids
• Previous allogeneic bone marrow transplant or double umbilical cord blood transplantation (dUCBT)

Contacts and Locations

Contacts

Contact: Matthew Galsky, MD; 212-824-5452; matthew.galsky@mssm.edu

Contact: Ahran Lee; 317-634-5842 ext 14; alee@hoosiercancer.org

Locations

United States, Illinois

University of Chicago Medical Center; Recruiting

Chicago, Illinois, United States, 60637

Contact: Glenna Smith Conley 773-834-2143 gsmith6@bsd.uchicago.edu

Principal Investigator: Peter O'Donnell, MD

United States, Maryland

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center; Recruiting

Baltimore, Maryland, United States, 21287

Contact: Victoria Sinibaldi 410-614-3209 sinibvi@jhmi.edu

Principal Investigator: Jean Hoffman-Censits, MD

United States, Michigan

Karmanos Cancer Center (Wyane State University); Recruiting

Detroit, Michigan, United States, 48201

Contact: Samantha Leacher 313-576-9752 leachers@karmanos.org

Principal Investigator: Ulka Vaishampayan, MD

United States, New York

Icahn School of Medicine at Mount Sinai; Recruiting

New York, New York, United States, 10029-6542

Contact: Matthew Galsky 212-824-5452 matthew.galsky@mssm.edu

United States, North Carolina

University of North Carolina at Chapel Hill; Recruiting

Chapel Hill, North Carolina, United States, 27599

Contact: Ellen Cohen 919-843-2448 ellen_cohen@med.unc.edu

Principal Investigator: Matthew Milowsky, MD

United States, Tennessee

Vanderbilt-Ingran Cancer Center; Recruiting

Nashville, Tennessee, United States, 37232

Contact: Matthew Fister 615-875-9979 matthew.c.fister@vumc.org

Principal Investigator: David Chism, MD

United States, Utah

Huntsman Cancer Institute University of Utah; Recruiting

Salt Lake City, Utah, United States, 84112-5550

Contact: Sumati Gupta, MD sumati.gupta@hci.utah.edu

Principal Investigator: Sumati Gupta, MD

Sponsors and Collaborators

Matthew Galsky

Icahn School of Medicine at Mount Sinai

AstraZeneca

Investigators

• Principal Investigator: Matthew Galsky, MD; Mt Sinai School of Medicine

More Information

• Responsible Party: Matthew Galsky, Sponsor Investigator, Hoosier Cancer Research Network
• ClinicalTrials.gov Identifier: NCT03448718
• Other Study ID Numbers: HCRN GU15-262
• First Posted: February 28, 2018
• Last Update Posted: February 11, 2020
• Last Verified: February 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:

Olaparib; Poly(ADP-ribose) Polymerase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents